Department of Clinical Sciences, Obstetrics and Gynecology, Umeå University, Umeå, Sweden.
Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden.
Trials. 2023 Mar 24;24(1):222. doi: 10.1186/s13063-023-07244-w.
The HOPPSA trial is a multi-center national registry-based randomized controlled trial to test the safety and effectiveness of performing opportunistic salpingectomy at hysterectomy to reduce the risk of epithelial ovarian cancer (EOC). The study protocol was first published in January 2019 and is available at https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-018-3083-8 . Here, we report amendments made to the study protocol since commencement of the trial.
The primary outcomes analyses have been changed. (1) Complications will be analyzed using binomial generalized estimating equation (GEE) with log link function, while the unadjusted analyses according to Miettinen and Nurminen will be performed as a sensitivity analysis. (2) Absolute change in Menopause Rating Scale (MRS) will primarily be analyzed using a mixed effects model, adjusted for baseline MRS and center as a random effect. (3) Time to EOC will be analyzed using the mixed effects Cox regression model with center as random effect, while the unadjusted log-rank test will be performed as a sensitivity analysis. The primary outcome Complications will be based solely on the specific assessment in the GynOp quality registry. The Clavien-Dindo classification will be evaluated as a secondary outcome. Furthermore, MRS is also measured three years postoperatively to better pinpoint the onset of menopausal symptoms.
The changes to the protocol mainly concern the analyses of data. No changes to recruitment, randomization, intervention, or follow-up of primary outcomes have been made. An interim analysis during 2021 concluded that the study should continue until the target sample size is reached.
ClinicalTrials.gov, NCT03045965 . Registered 8 February 2017.
HOPPSA 试验是一项多中心全国注册登记的随机对照试验,旨在测试在子宫切除术中进行机会性输卵管切除术以降低上皮性卵巢癌(EOC)风险的安全性和有效性。该研究方案于 2019 年 1 月首次发表,可在 https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-018-3083-8 上查看。在此,我们报告自试验开始以来对研究方案所做的修订。
主要结局分析已更改。(1)并发症将使用二项广义估计方程(GEE)进行分析,对数链接函数,而根据 Miettinen 和 Nurminen 的未调整分析将作为敏感性分析进行。(2)绝经评分量表(MRS)的绝对变化将主要使用混合效应模型进行分析,根据基线 MRS 和中心进行调整作为随机效应。(3)EOC 时间将使用中心作为随机效应的混合效应 Cox 回归模型进行分析,而未调整的对数秩检验将作为敏感性分析进行。主要结局并发症将仅基于 GynOp 质量登记的特定评估。Clavien-Dindo 分类将作为次要结局进行评估。此外,MRS 还在术后三年进行测量,以更好地确定绝经症状的发生。
方案的变化主要涉及数据分析。对主要结局的招募、随机化、干预和随访没有任何更改。2021 年进行的中期分析得出结论,该研究应继续进行,直到达到目标样本量。
ClinicalTrials.gov,NCT03045965。2017 年 2 月 8 日注册。